Genelux Corporation
GNLX · NASDAQ
Market closed$2.87$0.050000 (+1.77%)After hours $2.87 · 0.00%
Key statistics
Previous close$2.82
Open$2.82
Day high$2.88
Day low$2.82
52-week high$8.54
52-week low$2.29
Market cap107.96M
Volume77.17K
Average volume172.06K
P/E ratio-3.38
Forward P/E—
EPS-0.85
Dividend yield0.00%
Market context
Why it moved
GNLX (Genelux Corporation) edged higher on modest volume, likely supported by continued investor interest and positive sentiment in the biotech sector, as no specific major catalyst was identified in available news sources.
What is happening
Recent company-specific developments and publisher coverage.
Stock Titan · June 30, 2026Genelux says Olvi-Vec may reawaken platinum response in ovarian cancerGlobeNewswire · May 7, 2026Genelux Corporation Reports First Quarter Financial Results and Provides Business UpdatesQuiver Quantitative · March 19, 2026Genelux Corporation Announces Phase 3 Trial Data Timeline and Interim Results for Olvi-Vec in Ovarian and Lung Cancer, Alongside Leadership AppointmentQuiver Quantitative · January 8, 2026Genelux Corporation Announces Pricing of $20 Million Public Offering of Common StockGlobeNewswire · January 8, 2026Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common StockSeeking Alpha · November 13, 2025Genelux: Oncolytic Virus Player Near Phase 3 Finish Line, But Correction Likely (GNLX) Benzinga · June 30, 2026Genelux Announces Publication Of Translational And Clinical Findings From Phase 1b/2 VIRO-15 Trial Of Olvi-Vec-Primed Immunochemotherapy In Heavily Pretreated Patients With Platinum-R/R Ovarian Cancer Benzinga · March 20, 2026Benchmark Maintains Speculative Buy on Genelux, Lowers Price Target to $20 Benzinga · March 19, 2026Genelux Q4 EPS $(0.24) Misses $(0.21) Estimate Mt Newswire · January 8, 2026Genelux Shares Fall After $20 Million Stock Offering Priced Benzinga · January 8, 2026Genelux Prices ~$20M Public Offering Of 6.67M Shares At A Price Of $3/Share Benzinga · January 7, 2026Genelux Corporation Announces Proposed Public Offering Of Common Stock; No Terms Disclosed Benzinga · January 5, 2026Genelux Announces Interim Results From Two Ongoing Trials, Phase 1b/2 SCLC And Phase 2 VIRO-25, Evaluating Systemic Administration Of Olvi-Vec In Patients With Progressive SCLC And NSCLC Mt Newswire · January 2, 2026Genelux Names Jason Litten as Chief Medical Officer